Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL6529495 | 0.96 | — | — | |
| Guanidine SCHEMBL6851202 | 0.96 | — | — | |
| Guanidine SCHEMBL27473938 | 0.96 | — | — | |
| Guanidine SCHEMBL7755519 | 0.96 | — | — | |
| Guanidine SCHEMBL27492536 | 0.92 | — | — | |
| Guanidine SCHEMBL56028 | 0.92 | — | — | |
| Guanidine SCHEMBL29044101 | 0.92 | TSHR (0.31) | — | |
| Guanidine SCHEMBL1903839 | 0.92 | TSHR (0.31) | — | |
| Guanidine SCHEMBL31206959 | 0.88 | — | — | |
| Guanidine SCHEMBL28453453 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112662561-A | Normal-temperature bacteria ribonucleic acid protective agent and preparation method and application thereof | 中农新科(苏州)有机循环研究院有限公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-2520302-B1 | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy | CLEVELAND CLINIC FOUNDATION (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-1630229-B1 | Melanoma antigens | US HEALTH (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-2520302-A1 | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy | The Cleveland Clinic Foundation (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8273724-B2 | Melanoma antigens and their use in diagnostic and therapeutic methods | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1542701-B1 | STROMAL CELL-DERIVED FACTOR-1 MEDIATES STEM CELL HOMING AND TISSUE REGENERATION IN ISCHEMIC CARDIOMYOPATHY | CLEVELAND CLINIC FOUNDATION (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8137914-B2 | Allelic fetal plasma protein for use as diagnostic/prognostic tool in detection of hematopoietic cell proliferative disorders | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110287043-A1 | MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-11-24 | — | — | US | disclosed |
| US-8030280-B2 | Melanoma antigens and their use in diagnostic and therapeutic methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2311952-A2 | Antibodies to MRT-1 protein or fragments thereof | The United States Of America,As Represented By The Secretary, Department Of Health & Human Services (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-0584238-A1 | INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF | CHIRON CORPORATION (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0550661-A1 | GRO GENES, PROTEINS, AND USES THEREOF | CHIRON CORPORATION (US) | 1993-07-14 | — | — | EP | disclosed |
| EP-0534978-A1 | INTERLEUKIN-1 ANTAGONIST AND USES THEREOF | CHIRON CORPORATION (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992020795-A1 | INHIBITOR OF NF-λB TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF | CETUS ONCOLOGY CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992006196-A1 | GRO GENES, PROTEINS, AND USES THEREOF | CETUS ONCOLOGY CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
| WO-1991017249-A1 | INTERLEUKIN-1 ANTAGONIST AND USES THEREOF | CETUS CORPORATION (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4898814-A | A cDNA clone for human tyrosinase | DONALD GUTHRIE FOUNDATION FOR MEDICAL RESEARCH, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0290504-A4 | A cDNA CLONE FOR HUMAN TYROSINASE. | GUTHRIE DONALD FOUND MED RES (US) | 1989-09-19 | — | — | EP | disclosed |
| EP-0290504-A1 | A cDNA CLONE FOR HUMAN TYROSINASE | DONALD GUTHRIE FOUNDATION FOR MEDICAL RESEARCH, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988002372-A1 | A cDNA CLONE FOR HUMAN TYROSINASE | DONALD GUTHRIE FOUNDATION FOR MEDICAL RESEARCH, IN (US) | 1988-04-07 | — | — | WO | disclosed |